epirubicin has been researched along with Inflammatory Breast Cancer in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, T; Eguchi, S; Hayashi, H; Hidaka, M; Itoh, S; Kanetaka, K; Kawaguchi, Y; Kobayashi, K; Kuba, S; Meng, X; Morita, M | 1 |
| Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Chia, S; Cortés, J; Eniu, A; Harvey, V; Hegg, R; Hickish, T; McNally, V; Ratnayake, J; Ross, G; Schneeweiss, A; Seo, JH; Tausch, C; Tsai, YF | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Bachelot, T; Bidard, FC; Bonneterre, J; Campone, M; Charafe-Jauffret, E; Ferrero, JM; Gligorov, J; Hernandez, J; Lerebours, F; Lévy, C; Petit, T; Pierga, JY; Roché, H; Viens, P | 1 |
| Bachelot, T; Boher, JM; Delva, R; Dohollou, N; Eymard, JC; Fabbro, M; Ferrero, JM; Gonçalves, A; Leduc, B; Lemonnier, J; Lerebours, F; Linassier, C; Lotz, JP; Martin, AL; Mouret-Reynier, MA; Pierga, JY; Roché, H; Viens, P | 1 |
| Andre, F; Autret, A; Bachelot, T; Bertucci, F; Bidard, FC; Boher, JM; Bonneterre, J; Campone, M; Charafe-Jaufret, E; Dalenc, F; Eymard, JC; Ferrero, JM; Gligorov, J; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Proudhon, C; Romieu, G; Soulie, P; Viens, P | 1 |
| Czeglédi, F; Eckhardt, S; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Kásler, M; Láng, I; Polgár, C; Torday, L; Urbán, L | 1 |
| Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C | 1 |
| Anan, K; Ikejiri, K; Kudaka, M; Kuroki, S; Mitsuyama, S; Nakafusa, Y; Namba, K; Nishimura, R; Ohchi, T; Oikawa, T; Rai, Y; Saimura, M; Tamura, K; Toyoshima, S | 1 |
| Bauerfeind, I; Burghardt, S; Ditsch, N; Hinke, A; Kahlert, S; Konecny, GE; Lenhard, M; Löhrs, B; Loibl, S; Toth, B; Untch, M; Vodermaier, A; Von Koch, F; VON Minckwitz, G | 1 |
7 trial(s) available for epirubicin and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Heart; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2014 |
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2017 |
Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
5 other study(ies) available for epirubicin and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Sentinel Lymph Node Biopsy; Triple Negative Breast Neoplasms | 2022 |
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Epirubicin; Factor Xa Inhibitors; Fatal Outcome; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Male; Oxonic Acid; Pyridines; Radiotherapy, Intensity-Modulated; Skin Neoplasms; Syndrome; Tegafur; Thiazoles; Thrombophilia | 2019 |
Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Inflammatory Breast Neoplasms; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heart; Humans; Inflammatory Breast Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Pneumonitis; Survival Rate; Tamoxifen; Time Factors; Vincristine | 2012 |
[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Taxoids | 2012 |